Abbott Laboratories announced Kevin Conroy's appointment to its Board, approved the 2026 Incentive Stock Program with 140M share authorization, amended bylaws to expand Board to 13 members, and reported strong shareholder support for all Annual Meeting proposals.
Key takeaways
Kevin Conroy named to Abbott's Board of Directors on April 24, 2026.
Shareholders approved Abbott Laboratories 2026 Incentive Stock Program (95.82% for) replacing 2017 program with 140M share pool.
Board amended bylaws to increase from 12 to 13 directors effective April 24, 2026.
All 12 incumbent directors re-elected with overwhelming majorities (over 90% FOR each).
Auditor ratification, executive compensation (90.35% FOR), and employee stock plans received strong approval.